Ucb Manufacturing Inc

Information may not be reliable

At UCB our sense of purpose is to help people suffering from severe central nervous system or immunological disorders lead normal, everyday lives. Our ambition is to offer them innovative new medicines and ground-breaking solutions that go beyond the drug. We are committed to enabling cutting-edge scientific research that is driven by the patients' needs.

UCB, headquartered in Brussels, Belgium, is a global biopharma company with a team of over 8000 talented employees, a strong market presence in more than 40 countries, 3.1 billion in revenue (2009) and numerous strategic partnerships across the industry.

IT @ UCBWe operate in the cutting-edge industry of biopharmaceuticals, which requires the brightest minds working in teams. That includes UCB IT professionals who play an absolutely critical role as technology enables us to bring our aspirations to fruition

Groundbreaking Ceremony, June 4UCB started construction of its biotechnology pilot plant in Braine-lAlleud, Belgium

Epratuzumab phase IIb data presented at ACR show pipeline drug had positive effect in patients suffering from moderate to severe systemic lupus erythematosus 09-Nov-2010
New Cimzia (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations with Active Rheumatoid Arthritis (RA) 09-Nov-2010
Interim Report - Intense growth of Cimzia, Vimpat and Neupro 21-Oct-2010
UCB and Synosia Therapeutics sign strategic alliance in neurology 12-Oct-2010